Matrixx Prompts Supreme Court To Consider What Firms Must Disclose
This article was originally published in The Tan Sheet
Executive Summary
A class action suit against Zicam Cold Remedy maker Matrixx Initiatives heads to the Supreme Court, in a case that could affect the number of securities actions brought against pharma companies
You may also be interested in...
Search For Balance Drives Supreme Court Debate In Matrixx Case
In litigation between Matrixx Initiatives and shareholders, the Supreme Court appears concerned with striking a balance between requiring the disclosure of any facts that could affect investors' decisions and the release of so much information that important facts are obscured.
Trade Groups Back Matrixx On AER Disclosure In Supreme Court Case
Blanket disclosure of all adverse event reports would be "detrimental to investors and consumers," trade groups say in a brief supporting Matrixx Initiatives in its dispute with shareholders
Zicam Maker Matrixx' Sales Plummet While Legal Costs Climb
Zicam manufacturer Matrixx Initiatives' sales dropped more than 50 percent in its most recent quarter as its legal costs continue to grow